APA (7th ed.) Citation
(2022). Genome-wide CRISPR screen identifies synthetic lethality between DOCK1 inhibition and metformin in liver cancer. Protein & Cell.
Chicago Style (17th ed.) Citation
"Genome-wide CRISPR Screen Identifies Synthetic Lethality Between DOCK1 Inhibition and Metformin in Liver Cancer." Protein & Cell 2022.
MLA (9th ed.) Citation
"Genome-wide CRISPR Screen Identifies Synthetic Lethality Between DOCK1 Inhibition and Metformin in Liver Cancer." Protein & Cell, 2022.
Warning: These citations may not always be 100% accurate.